

Syngene opens R&D centre in Hyderabad

17 February 2020 | News | By Kalyani Sharma

The centre was inaugurated by K.T Rama Rao, Minister for Industries, IT, MA & UD, Government of Telangana



Syngene International Limited, global contract research organization has announced the commissioning of the first phase of its new R&D centre in Hyderabad.

The centre, located in Genome Valley, is spread across 52000 sq. ft. with an initial strength of around 150 scientists. This is the Company's first operational research centre outside Bengaluru. When fully commissioned by the end of this year at an investment of Rs. 167 Cr, it will cover a total of 94000 sq. ft. and house around 270 scientists.

The centre was inaugurated by K.T Rama Rao, Minister for Industries, IT, MA & UD, Government of Telangana, in the presence of Jayesh Ranjan, IAS, Principle Secretary, Industries and Commerce, Government of Telangana and Shakthi Nagappan, Director (Life Sciences & Pharma) and Chief Executive Officer, Hyderabad Pharma City, together with senior leaders from Syngene.

Speaking on the occasion, K.T Rama Rao said, "We are happy that Syngene International Limited has selected Telangana for setting up their new R&D center. This is a testimony to one of the accomplishments of BioAsia which has been able to showcase the immense potential, opportunity, and support the state offers. We have been focusing on the Life Sciences sector and the Genome Valley was conceptualised to provide all the necessary infrastructure and support systems for life science R&D activities. Syngene's presence is surely a boost for the state's vision to be a biotech hub."

Kiran Mazumdar Shaw, Managing Director, Syngene International Ltd. said, "We are delighted to set up our new R&D centre in Genome Valley, Telangana, recognised as a leading global biotech hub. I congratulate the Government of Telangana on their vision and pioneering efforts to create an environment that fosters the growth and development of the biotechnology industry."

Jonathan Hunt, Chief Executive Officer, Syngene International said, "The inauguration of this site in Genome Valley today marks an important step for the company. With increasing demand for our research services, we needed to find a location that offered the right environment to drive scientific innovation and seamless delivery. This means not just having the ability to build, equip and maintain world class laboratories, we also need to be able to attract top scientists in chemistry, biology, biometrics and other disciplines. Genome Valley has all the requisite infrastructure and a comprehensive science eco-system

to allow us to deliver cutting edge, innovative scientific research outside Bangalore for the first time.”

Genome Valley is India's first purpose-built cluster for life sciences R&D activities spread across 600 sq km. Syngene's new R&D centre is located in MN Park at the heart of the Genome Valley.

The new R&D centre is fully digitised based on an internet-based, innovative, analytical laboratory solution that enables anytime, anywhere, monitoring; remote and secure access; and minimizes system downtime by monitoring the operational status of the systems. The centre also has other digitisation and automation features including electronic laboratory notebooks and analytical intelligence.

The building benefits from environment-friendly measures such as energy conservation through the use of solar power and limited plastic use. The safety features of the centre include laboratories built with fire-rated walls and panels, a dedicated flame proof area for storage of hazardous materials away from the laboratories and dedicated water lines for fire hydrant and sprinkler systems.

Initially, the Company will offer Discovery Chemistry services from Hyderabad. In the next phase, other research services will move to this centre providing research to the world's leading pharmaceutical companies.

Syngene currently operates through multiple facilities in Bengaluru spread across an area of 1.5 million sq ft. comprising state-of-the art research and manufacturing facilities. These facilities have successfully cleared multiple global regulatory inspections including the USFDA, EMA and PMDA.